Estrella Immunopharma (ESLA) Operating Income (2021 - 2026)

Estrella Immunopharma (ESLA) has reported Operating Income for 6 consecutive years, with -$2.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Income rose 62.41% year-over-year to -$2.1 million in Q2 2026; TTM through Jun 2026 was -$9.8 million, a 50.5% increase from a year earlier, with the FY2025 full-year figure at -$13.1 million, down 48.09% from the prior year.
• Operating Income was -$2.1 million for Q2 2026 at Estrella Immunopharma, up from -$2.3 million in the prior quarter.
• Over five years, Operating Income peaked at -$144940.0 in Q1 2022 and troughed at -$8.4 million in Q1 2023.
• A 5-year average of -$3.1 million and a median of -$2.2 million in 2025 frame the typical range for Operating Income.
• Across the five-year window, Operating Income sank 17597.19% in 2022 and soared 94.4% in 2024, its largest moves.
• Over 5 years, Operating Income stood at -$5.6 million in 2022, then surged by 81.91% to -$1.0 million in 2023, then slumped by 333.75% to -$4.4 million in 2024, then soared by 85.31% to -$650525.0 in 2025, then tumbled by 220.39% to -$2.1 million in 2026.
• The last three Operating Income figures came in at -$2.1 million (Q2 2026), -$2.3 million (Q1 2026), and -$650525.0 (Q4 2025), per Business Quant data.